TB-500 Dosing Protocol
TB-500 (Thymosin Beta-4 fragment) is studied for tissue repair, cell migration, and anti-inflammatory activity. Protocols commonly use a loading phase followed by maintenance. This guide summarizes dosing approaches from published research.
Key Points
Step-by-Step Guide
Define Study Parameters
Establish the tissue type under investigation—muscle, tendon, ligament, or cardiac. TB-500 research spans multiple repair models and objectives shape the dosing approach.
Initiate Loading Phase
Loading protocols use 2-2.5 mg twice per week for 4-6 weeks. This front-loaded approach saturates target tissues and initiates repair cascades.
Transition to Maintenance
After loading, reduce to 2-2.5 mg once weekly or biweekly. Maintenance sustains elevated thymosin beta-4 levels with reduced peptide consumption.
Choose Injection Site
Subcutaneous injection is standard. TB-500 is systemic, so injection site is less critical than with localized peptides. Rotate sites to minimize irritation.
Track Recovery Markers
Monitor inflammatory markers, imaging, and functional recovery at 2-week intervals throughout the study duration.
Warnings & Precautions
- !TB-500 is for research only and is not FDA-approved.
- !Loading phase doses are higher—ensure accurate reconstitution.
- !Exclude subjects with active cancer due to angiogenic properties.
- !Store lyophilized TB-500 at -20°C for long-term stability.
Frequently Asked Questions
What is the standard TB-500 loading dose?
The most common loading protocol is 2-2.5 mg twice per week (4-5 mg total/week) for 4-6 weeks.
How does TB-500 maintenance dosing work?
After loading, frequency drops to once weekly or biweekly at the same per-dose amount, maintaining tissue levels with less total peptide.
Is TB-500 injected locally or systemically?
TB-500 acts systemically due to its role in actin regulation. Subcutaneous injection at any convenient site is standard.